We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Stem Cell Derived Cardiomyocytes in Drug Safety Evaluations: Lessons Learned from the Comprehensive in Vitro Proarrhythmia Assay (CiPA) Initiative

Video   Oct 18, 2016

 

The Comprehensive in Vitro Proarrhythmia Assay (CiPA) represents a new paradigm for directly assessing proarrhythmic risk based upon mechanistic assessments of cellular proarrhythmia linked to Torsades-de-Pointes proarrhythmia. Human stem cell derived cardiomyocytes (hSC-CMs) play a critical role in this initiative, serving to confirm in silico reconstructions of electrophysiologic effects of drugs. The utility of this approach involves consideration of the higher throughput approaches to be used (multielectrode arrays or voltage-sensing optical technologies) as well as consideration of the ability of hSC-CM’s to faithfully and reproducibly recapitulate cellular proarrhythmic events. Multiple publications (as well as a HESI-CiPA Pilot study) point to the utility of hSC-CM’s to detect delayed repolarization as well as other repolarization abnormalities. However, such studies are typically small and conducted unblinded, with a potential bias in the selection of test agents that may not be fully characterized in regards to proarrhythmic risk ranking. Evolving datasets from an ongoing validation study with hSC-CM’s will provide an assessment of the utility of hSC-CM’s for evaluating proarrhythmic liabilities early in drug discovery as well as in later regulatory-approvals of new drugs.

 
 
 
 

Recommended Videos

Operetta CLS High-Content Analysis System

Video

The Operetta CLS system is part of PerkinElmer's comprehensive HCS portfolio – from HCS systems and microplates to automation and informatics.

WATCH NOW

In Pursuit of a Universal Antivenom

Video

When it comes to venomous snake bites, time is of the essence.
Find out how researchers are working to find an effective and affordable universal antivenom.

WATCH NOW

ULTImate YChemH: a powerful tool for drug target deconvolution

Video

What if I told you Hybrigenics Services can help you make the right decisions and optimize the success rate of your drug discovery and development programs?
Watch how with our animation video and discover our optimized ULTImate YChemH technology for drug target deconvolution.

WATCH NOW

 

Like what you just watched? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE